SCHEMBL1989233

SCHEMBL1989233

CC(C)NC(=N)Nc1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
LMNA P02545 4/20 0.44
CNR1 P21554 2/20 0.43
TSHR P16473 1/20 0.43
CYP1A2 P05177 1/20 0.42
ADRA2A P08913 1/20 0.42
CYP2D6 P10635 1/20 0.42
DRD1 P21728 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KCNH2 Q12809 1/20 0.42
NPC1 O15118 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 3/20 0.41
RAB9A P51151 3/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Proguanil SCHEMBL45726 0.91 LMNA (0.41) ALDH1A1MEN1KMT2ALMNACNR1
Proguanil SCHEMBL218859 0.90 LMNA (0.40) ALDH1A1MEN1KMT2ALMNACNR1
Proguanil SCHEMBL2543837 0.90 LMNA (0.40) ALDH1A1MEN1KMT2ALMNACNR1
Proguanil SCHEMBL9247094 0.85 MEN1 (0.40) ALDH1A1MEN1KMT2ALMNACNR1
Proguanil SCHEMBL2539379 0.84 MEN1 (0.46) ALDH1A1MEN1KMT2ALMNACNR1
SCHEMBL2350583 0.83 ALDH1A1 (0.49) ALDH1A1MEN1KMT2ALMNACNR1
SCHEMBL9881079 0.83 LMNA (0.40) ALDH1A1MEN1KMT2ALMNACNR1
Proguanil SCHEMBL2545386 0.82 ALDH1A1 (0.43) ALDH1A1MEN1KMT2ALMNACNR1
SCHEMBL2287103 0.81 NPC1 (0.54) ALDH1A1MEN1KMT2ALMNACNR1
SCHEMBL1983057 0.80 EPHX1 (0.50) ALDH1A1MEN1KMT2ALMNAADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4180482-B1 MOISTURE-CURABLE COMPOSITION NITTO KASEI CO LTD (JP) 2025-12-03 EP disclosed
US-12479869-B2 Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product NITTO KASEI CO., LTD. (JP) 2025-11-25 US disclosed
EP-4174053-B1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT NITTO KASEI CO LTD (JP) 2025-11-19 EP disclosed
CN-115516041-B Curing catalyst for curing polymer, method for producing same, moisture-curable composition, and method for producing cured product 日东化成株式会社 2024-06-28 CN disclosed
US-20230234976-A1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT NITTO KASEI CO., LTD. (JP) 2023-07-27 US disclosed
EP-4180482-A1 MOISTURE-CURABLE COMPOSITION Nitto Kasei Co., Ltd. (JP) 2023-05-17 EP disclosed
EP-4174053-A1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT Nitto Kasei Co., Ltd. (JP) 2023-05-03 EP disclosed
EP-2837660-B1 CURABLE COMPOSITION, AND CURED SYNTHETIC RESIN USING SAME UNIV MIE (JP) 2021-07-14 EP disclosed
CN-106574114-B Curable organopolysiloxane composition 瓦克化学股份公司 2019-10-15 CN disclosed
US-10301433-B2 Curable organopolysiloxane compositions WACKER CHEMIE AG (DE) 2019-05-28 US disclosed
CN-102165016-B Curable composition and cured product thereof KANEKA CORP 2014-03-12 CN disclosed
EP-2338938-B1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF KANEKA CORP (JP) 2013-07-31 EP disclosed
US-20110237723-A1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF KANEKA CORPORATION (JP) 2011-09-29 US disclosed
CN-102165016-A Curable composition and cured product thereof KANEKA CORP 2011-08-24 CN disclosed
EP-2338938-A1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF Kaneka Corporation (JP) 2011-06-29 EP disclosed
US-7960459-B2 Curable composition KANEKA CORPORATION (JP) 2011-06-14 US disclosed
EP-2267083-A1 CURABLE COMPOSITION AND CURED MATERIAL Kaneka Corporation (JP) 2010-12-29 EP disclosed
EP-1990371-B1 CURABLE COMPOSITION KANEKA CORP (JP) 2010-05-05 EP disclosed
US-20090186993-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2009-07-23 US disclosed
EP-1990371-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-11-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479869-B2 Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product KDM2B, SETDB1, ASH2L ALDH1A1 615/4885MEN1 684/4885KMT2A 150/4885
US-20230234976-A1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT KDM2B, SETDB1, ASH2L ALDH1A1 615/4885MEN1 684/4885KMT2A 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.